CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 254 enrolled
Drug / intervention
MP-214 3mg +3 moredrug
Likely dose
MP-214 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01626872
NCT01626872Phase 3Completed
CompareCT.gov

Long-Term Extension Study of MP-214 in Patients With Schizophrenia

Tanabe Pharma Corporation·interventional·Posted Jun 25, 2012·Updated Jan 5, 2026

In Brief

A Phase 3 clinical trial evaluating MP-214 3mg, MP-214 6mg, and 2 other interventions for Schizophrenia. Completed, enrolled 254 participants across 3 sites in 3 countries.

Detailed Summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan, South Korea, Taiwan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2012
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 14.0 years ago

Interventions

MP-214 3mgdrug

In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

MP-214 6mgdrug

In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

MP-214 9mgdrug

In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

Risperidone 4mgdrug

In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).